Clinical Trial Update: Long Term Safety Assessment of SER120 in Patients With Nocturia [Phase 3]

View source ↗

Summary

Long-term safety assessment results for SER120 in nocturia patients from a Phase 3 trial have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nocturia

Drugs mentioned

• SER120

Snippet

Sponsor: Serenity Pharmaceuticals, Inc. | Conditions: Nocturia | Phase 3 | Status: COMPLETED | Results posted: 2021-01-20